Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients

Despite their theoretical rationale, nicotinic alpha-7 acetylcholine (nα(7)) receptor agonists, have largely failed to demonstrate efficacy in placebo-controlled trials in schizophrenia. AVL-3288 is a nα(7) positive allosteric modulator (PAM), which is only active in the presence of the endogenous l...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuropsychopharmacology
Auteurs principaux: Kantrowitz, Joshua T., Javitt, Daniel C., Freedman, Robert, Sehatpour, Pejman, Kegeles, Lawrence S., Carlson, Marlene, Sobeih, Tarek, Wall, Melanie M., Choo, Tse-Hwei, Vail, Blair, Grinband, Jack, Lieberman, Jeffrey A.
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7298033/
https://ncbi.nlm.nih.gov/pubmed/32015461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41386-020-0628-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires